Through inhouse R&D and cooperation with research institutions and colleges, we have probed into the field of artificial intelligence and drug discovery. Galixir has already published nearly 20 papers in top journals and conference proceedings, covering molecular generation, property prediction, virtual screening and so forth. And our original models have maintained the world’s leading performance.
Evolved from tools and experience of medicinal chemistry, computational chemistry and biology, the Pyxir platform provides end-to-end solutions in preclinical drug discovery such as molecular generation, property prediction, virtual screening and optimization.
We highly value the significance of project data security. Project-specific data is trained using federated-learning algorithm to ensure performance as well as independence. Meanwhile, based on the project information isolation mechanism and authority management system embedded in Pyxir, confidentiality is ensured in data transmission and analysis.
Through collaboration with our strategic partners, we are developing pipelines on therapeutic areas including central nervous system diseases, autoimmune diseases, tumors, respiratory diseases. We have made good progress in both inhibitor development and agonist development. With rich experience in machine learning application, our AI engineering team is able to transfer our model advantages into project productivity.